AR057082A1 - Derivados de ciclohexilaminisoquinolona - Google Patents

Derivados de ciclohexilaminisoquinolona

Info

Publication number
AR057082A1
AR057082A1 ARP060103200A ARP060103200A AR057082A1 AR 057082 A1 AR057082 A1 AR 057082A1 AR P060103200 A ARP060103200 A AR P060103200A AR P060103200 A ARP060103200 A AR P060103200A AR 057082 A1 AR057082 A1 AR 057082A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
heterocyclyl
aryl
cycloalkyl
Prior art date
Application number
ARP060103200A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR057082A1 publication Critical patent/AR057082A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)

Abstract

Son estos compuestos utiles para el tratamiento y/o prevencion de enfermedades asociadas con la Rho-quinasa y/o la fosforilacion mediada por la Rho-quinasa de la fosfatasa de la cadena ligera de miosina, se divulgan composiciones que contienen tales compuestos. Reivindicacion 1: Un compuesto de formula (1), o de formula (1), donde: R1 es H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, (alquilenoC1-6)0-1-cicloalquiloC3-8, (alquilenoC1-6)0-1-heterocicliloC5-10, alquilenoC1-6]0-1-ariloC6-10, C(O)-alquiloC1-6, C(O)-alqueniloC2-6, C(O)-alquiniloC2-6, C(O)-(alquilenoC1-6)0-1-cicloalquiloC3-8, C(O)-(alquilenoC1-6)0-1-heterocicliloC5-10, o C(O)-(alquilenoC1-6)0-1-ariloC6-10; R2 es H, alquilo C1-6, (alquilenoC1-C6)0-1-R1', (alquilenoC1-6)0-1- O-alquiloC1-6, (alquilenoC1-6)0-1-O-R', (alquilenoC1-6)0-1-NH2, (alquilenoC1-6]0-1-NH-alquiloC1-6, (alquilenoC1-6)0-1, -N(alquiloC1-6)2, (alquilenoC1-6)0-1-CH(R')2, (alquilenoC1-6)0-1-C(O)-R', (alquilenoC1-6)0-1-C(O)NH2, (alquilenoC1-6)0-1-C(O)NH- R', o (alquilenoC1-6)0-1-C(O)N(R')2; R3 es H, halogeno, CN, alquilo C1-6, alquilenoC1-6-R', OH, O-R'', NH2, NHR'', NR''R'' o NH-C(O)-R''; R4 es H, halogeno, hidroxi, CN, alquilo C1-6, cicloalquilo C3-8, alquilenoC1-6-R'; R5 es H, halogeno, CN, NO2, alquilo C1-6, alquenilo C2-6, R', alquilenoC1-6-ariloC6-10, alquenilenoC2-6-ariloC6-10, alquilenoC1-6-heterocicliloC5-10, NH2, NH-R', NH-SO2H, NH-SO2-alquiloC1-6, NH-SO2-R', NH-C(O)-alquiloC1-6, NH-C(O)-R', C(O)N(alquiloC1-6)2, C(O)OH o C(O)O- alquiloC1-6; R6 y R6' son independientemente entre sí H, R', alquilo C1-8, alquilenoC1-6-R', alquilenoC1-6-O-alquilo(C1-6, alquilenoC1-6-O-R', alquilenoC1-6-CH(R')2, alquilenoC1-6-C(O)-R', alquilenoC1-6-C(O)NH2, alquilenoC1-6-C(O)NH-R', o alquilenoC1-6-C(O)N(R')2; R7 y R8 son independientemente entre sí H, halogeno, CN, NO2, alquilo C1-6, O-alquiloC1-6, O-(alquilenoC1-6)0-1-R', alquenilo C2-6, R', alquenilenoC2-6-ariloC6-10, alquilenoC1-6-R', NH2, NH-R', NH-SO2H, NH-SO2-alquiloC1-6, NH-SO2-R', SO2-NH2, SO2-NHR', NH-C(O)-alquiloC1-6, NH-C(O)-R', C(O)N(alquiloC1-6)2, C(O)OH o C(O)O-alquiloC1-6; R9 es halogeno o alquilo C1-6; n es 0, 1, 2, 3 o 4; y L es O o O-alquilenoC1-6; donde R' es cicloalquilo C3-8, heterociclilo C5-10 o arilo C6-10; y R'' es cicloalquilo C3-8, heterociclilo C5-10, arilo C6-10, alquilo C1-6, alquilenoC1-6-R', alquilenoC1-6-O-alquiloC1-6, alquilenoC1-6-O-R' o alquilenoC1-6-NRxRy; y donde Rx y Ry son independientemente entre sí alquilo C1-6, heterociclilo C5-10, arilo C6-10, alquilenoC1-4-heterocicliloC5-10, alquilenoC1-4-arilo C6-10, alquilenoC1-4-NH-alquiloC1-6, alquilenoC1-4-N(alquiloC1-6)2, alquilenoC1-4-N(ariloC6-10)2, o alquilenoC1-4-N(heterocicliloC5-10)2; y donde en los restos R4, R5, R7 y R8 uno átomo de hidrogeno del grupo alquilo o alquileno puede estar opcionalmente sustituido con OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONH2, CONHCH3 o CON(CH3)2 o un grupo alquilo o alquileno puede estar halogenado una o más veces; y/o sus sales farmacéuticamente aceptables y/o formas estereoisoméricas y/o derivados fisiologicamente funcionales.
ARP060103200A 2005-07-26 2006-07-25 Derivados de ciclohexilaminisoquinolona AR057082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05016153 2005-07-26

Publications (1)

Publication Number Publication Date
AR057082A1 true AR057082A1 (es) 2007-11-14

Family

ID=35115842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103200A AR057082A1 (es) 2005-07-26 2006-07-25 Derivados de ciclohexilaminisoquinolona

Country Status (37)

Country Link
US (2) US8609691B2 (es)
EP (1) EP1912949B1 (es)
JP (1) JP5049970B2 (es)
KR (1) KR101336678B1 (es)
CN (1) CN101228132B (es)
AR (1) AR057082A1 (es)
AT (1) ATE521595T1 (es)
AU (1) AU2006274246B2 (es)
BR (1) BRPI0614063A2 (es)
CA (1) CA2615663C (es)
CR (1) CR9604A (es)
CY (1) CY1112085T1 (es)
DK (1) DK1912949T3 (es)
DO (1) DOP2006000177A (es)
EC (1) ECSP088136A (es)
ES (1) ES2372067T3 (es)
GT (1) GT200600327A (es)
HK (1) HK1123036A1 (es)
HN (1) HN2008000130A (es)
HR (1) HRP20110839T1 (es)
IL (1) IL188949A (es)
MA (1) MA29639B1 (es)
MX (1) MX2008000956A (es)
MY (1) MY146644A (es)
NI (1) NI200800024A (es)
NO (1) NO20080965L (es)
NZ (1) NZ565669A (es)
PE (1) PE20070181A1 (es)
PL (1) PL1912949T3 (es)
PT (1) PT1912949E (es)
RS (1) RS52241B (es)
RU (1) RU2440988C2 (es)
SI (1) SI1912949T1 (es)
TN (1) TNSN08038A1 (es)
TW (1) TWI412521B (es)
WO (1) WO2007012422A1 (es)
ZA (1) ZA200710952B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006264043B2 (en) 2005-06-28 2012-04-26 Sanofi-Aventis Isoquinoline derivatives as inhibitors of Rho-kinase
CN101228132B (zh) 2005-07-26 2012-10-10 塞诺菲-安万特股份有限公司 作为Rho-激酶抑制剂的环己基胺异喹啉酮衍生物
UA93882C2 (ru) 2005-07-26 2011-03-25 Санофи-Авентис Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
JP5271909B2 (ja) * 2006-09-11 2013-08-21 エム・エス・ディー・オス・ベー・フェー 2−(1−オキソ−1h−イソキノリン−2−イル)アセトアミド誘導体
BRPI0720862A2 (pt) 2006-12-27 2014-02-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
WO2008077555A2 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
CN101611012B (zh) * 2006-12-27 2012-11-14 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹啉衍生物
KR101494452B1 (ko) 2006-12-27 2015-02-16 사노피 사이클로알킬아민 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
MY155009A (en) 2006-12-27 2015-08-28 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
KR20090094338A (ko) 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
CL2008000973A1 (es) 2007-04-05 2009-01-02 Astrazeneca Ab Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
JP5524071B2 (ja) * 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドt型カルシウムチャネルアンタゴニスト
RU2532481C2 (ru) 2008-06-24 2014-11-10 Санофи-Авентис Би- и полициклические замещенные производные изохинолина и изохинолинона, полезные в качестве ингибиторов rho-киназы
PL2313374T3 (pl) * 2008-06-24 2014-03-31 Sanofi Sa 6-podstawione izochinoliny i izochinolinony
KR101638326B1 (ko) * 2008-06-24 2016-07-12 사노피 Rho 키나제 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논
BRPI0917936A2 (pt) * 2008-08-25 2017-07-11 Irm Llc Moduladores de via hedgehog
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
TW201443023A (zh) * 2013-01-18 2014-11-16 必治妥美雅史谷比公司 作爲rock抑制劑之酞□酮及異喹啉酮
FI3640241T3 (fi) 2013-10-18 2023-01-13 Bromodomeeni-inhibiittorit
CA2927830A1 (en) * 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2016180918A1 (en) 2015-05-12 2016-11-17 Platod Combination of pharmacological and microfluidic features for improved platelets production
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
WO2019236879A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN114874236B (zh) * 2022-06-24 2023-05-05 中国工程物理研究院化工材料研究所 一种五元氮杂稠环骨架及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
WO1992002476A1 (en) 1990-07-31 1992-02-20 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE69737631T3 (de) 1996-08-12 2011-08-18 Mitsubishi Tanabe Pharma Corp. MEDIKAMENTE ENTHALTEND Rho-KINASE INHIBITOREN
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
AU8872198A (en) 1997-08-29 1999-03-22 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
US6784192B2 (en) 2000-01-20 2004-08-31 Eisai Co., Ltd. Piperidine compound and pharmaceutical composition thereof
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
KR20050019918A (ko) * 2002-07-22 2005-03-03 아사히 가세이 파마 가부시키가이샤 5-치환 이소퀴놀린 유도체
WO2004009555A1 (ja) * 2002-07-22 2004-01-29 Asahi Kasei Pharma Corporation 5−置換イソキノリン誘導体
WO2004024717A1 (ja) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
ATE421324T1 (de) * 2003-03-11 2009-02-15 Novartis Ag Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
US20040225116A1 (en) 2003-05-08 2004-11-11 Payne Mark S. Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
EP1638939A2 (en) 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7826566B2 (en) 2003-08-22 2010-11-02 4Links Limited Communication system
WO2005030791A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
JP4794446B2 (ja) 2003-09-23 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリン系カリウムチャンネル阻害薬
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
JPWO2005035516A1 (ja) * 2003-10-10 2006-12-21 小野薬品工業株式会社 新規縮合複素環化合物およびその用途
EP1689719A1 (en) 2003-11-25 2006-08-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
JP4969049B2 (ja) * 2004-04-06 2012-07-04 株式会社アマダ 曲げ加工装置
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
EP1741525A1 (de) 2005-07-06 2007-01-10 Trumpf Werkzeugmaschinen GmbH + Co. KG Vorrichtung zur Aufnahme von plattenförmigen Materialien
UA93882C2 (ru) 2005-07-26 2011-03-25 Санофи-Авентис Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы
CN101228132B (zh) 2005-07-26 2012-10-10 塞诺菲-安万特股份有限公司 作为Rho-激酶抑制剂的环己基胺异喹啉酮衍生物
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
JP4033221B2 (ja) 2005-12-02 2008-01-16 ダイキン工業株式会社 冷媒加熱装置
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
KR101494452B1 (ko) 2006-12-27 2015-02-16 사노피 사이클로알킬아민 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
WO2008077555A2 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors

Also Published As

Publication number Publication date
ECSP088136A (es) 2008-02-20
MX2008000956A (es) 2008-03-27
ZA200710952B (en) 2008-11-26
KR101336678B1 (ko) 2013-12-04
DK1912949T3 (da) 2011-11-28
HN2008000130A (es) 2010-12-27
RU2008106926A (ru) 2009-09-10
NZ565669A (en) 2010-05-28
CY1112085T1 (el) 2015-11-04
JP2009502830A (ja) 2009-01-29
ES2372067T3 (es) 2012-01-13
IL188949A0 (en) 2008-04-13
MA29639B1 (fr) 2008-07-01
CR9604A (es) 2008-04-10
JP5049970B2 (ja) 2012-10-17
AU2006274246B2 (en) 2012-07-12
TW200800906A (en) 2008-01-01
ATE521595T1 (de) 2011-09-15
HRP20110839T1 (hr) 2011-12-31
US20110251226A1 (en) 2011-10-13
IL188949A (en) 2013-11-28
TNSN08038A1 (en) 2009-07-14
EP1912949A1 (en) 2008-04-23
RU2440988C2 (ru) 2012-01-27
CA2615663A1 (en) 2007-02-01
KR20080028970A (ko) 2008-04-02
WO2007012422A1 (en) 2007-02-01
PE20070181A1 (es) 2007-03-07
TWI412521B (zh) 2013-10-21
BRPI0614063A2 (pt) 2011-03-09
DOP2006000177A (es) 2007-06-15
HK1123036A1 (en) 2009-06-05
SI1912949T1 (sl) 2011-12-30
NO20080965L (no) 2008-02-22
CA2615663C (en) 2013-10-15
AU2006274246A1 (en) 2007-02-01
US8796458B2 (en) 2014-08-05
US8609691B2 (en) 2013-12-17
CN101228132B (zh) 2012-10-10
GT200600327A (es) 2007-02-05
EP1912949B1 (en) 2011-08-24
MY146644A (en) 2012-09-14
NI200800024A (es) 2009-03-03
RS52241B (en) 2012-10-31
PL1912949T3 (pl) 2012-01-31
US20080242699A1 (en) 2008-10-02
CN101228132A (zh) 2008-07-23
PT1912949E (pt) 2011-11-23

Similar Documents

Publication Publication Date Title
AR057082A1 (es) Derivados de ciclohexilaminisoquinolona
AR054868A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
AR054518A1 (es) Derivados de isoquinolina
AR064533A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos y su uso en la produccion de un medicamento para el tratamiento de enfermedades relacionadas con la inhibicion de la rho-quinasa.
AR064493A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos
AR072281A1 (es) Isoquinolinas e isoquinolinonas sustituidas
AR036586A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen
AR062224A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden.
AR064531A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la rho-quinasa
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
AR043682A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los contienen y su uso para el tratamiento del crecimiento celular anormal
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR050610A1 (es) Derivados de dihidropteridinona
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
ECSP034563A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
ECSP088114A (es) Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia
AR043959A1 (es) Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos
AR057576A1 (es) Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor

Legal Events

Date Code Title Description
FB Suspension of granting procedure